{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:44:33Z","timestamp":1793130273525,"version":"4.5.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.bmc.2024.117653","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T05:21:32Z","timestamp":1709270492000},"page":"117653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Bioisoteres for carboxylic acids: From ionized isosteres to novel unionized replacements"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7869-6835","authenticated-orcid":false,"given":"Adrian","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chatzopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117653_b0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/cmdc.201200585","article-title":"Carboxylic acid (bio)isosteres in drug design","volume":"8","author":"Ballatore","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.117653_b0010","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2164558","article-title":"Carboxylic acid bioisosteres in medicinal chemistry, synthesis and properties","author":"Bredael","year":"2022","journal-title":"J Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0015","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.2174\/0929867328666210820112126","article-title":"Recent developments in the practical application of novel carboxylic acid bioisosteres","volume":"29","author":"Horgan","year":"2022","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0020","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1021\/acs.jmedchem.5b01963","article-title":"Structure property relationships of carboxylic acid isosteres","volume":"59","author":"Lassalas","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/ps030210","article-title":"Comparisons of pKa and log P values of some carboxylic and phosphonic acids: Synthesis and measurement","volume":"3","author":"Franz","year":"2001","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.bmc.2024.117653_b0030","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1016\/S0968-0896(02)00239-0","article-title":"5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods","volume":"10","author":"Herr","year":"2002","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0035","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1021\/jo01093a006","article-title":"Tetrazole analogs of amino acids1","volume":"24","author":"McManus","year":"1959","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF01361878","article-title":"Synthesis of biheterocyclic\u03b1-amino acids","volume":"17","author":"Achamlale","year":"1999","journal-title":"Amino Acids"},{"key":"10.1016\/j.bmc.2024.117653_b0045","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/ci200521k","article-title":"The hydrogen bond environments of 1H-tetrazole and tetrazolate rings: the structural basis for tetrazole-carboxylic acid bioisosterism","volume":"52","author":"Allen","year":"2012","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2024.117653_b0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0968-0896(00)00270-4","article-title":"Synthesis and biological evaluation of 2-(3'-(1H-tetrazol-5-yl) bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGlu1 receptor antagonist","volume":"9","author":"Costantino","year":"2001","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0055","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1021\/ci9000234","article-title":"Hydrogen Bonding, Electrostatic Potential, and Molecular Design","volume":"49","author":"Kenny","year":"2009","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2024.117653_b0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0031-6989(83)80060-5","article-title":"Isosterism and molecular modification in drug design : Tetrazole analogue of GABA : Effects on enzymes of the \u03b3-aminobutyrate system","volume":"15","author":"Kraus","year":"1983","journal-title":"Pharmacol Res Commun"},{"key":"10.1016\/j.bmc.2024.117653_b0065","article-title":"Exploring QSAR.: Fundamentals and applications in chemistry and biology","author":"Hansch","year":"1995","journal-title":"Am Chem Soc"},{"key":"10.1016\/j.bmc.2024.117653_b0070","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1021\/acsmedchemlett.2c00114","article-title":"Bioisostere effects on the EPSA of common permeability-limiting groups","volume":"13","author":"Ecker","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117653_b0075","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1021\/jm00112a031","article-title":"Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives","volume":"34","author":"Carini","year":"1991","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0080","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/med.2610120203","article-title":"The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist","volume":"12","author":"Duncia","year":"1992","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2024.117653_b0085","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1021\/jm980499w","article-title":"An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and Sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations","volume":"42","author":"Mavromoustakos","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0090","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2165\/00003088-200544080-00003","article-title":"Clinical pharmacokinetics of losartan","volume":"44","author":"Sica","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bmc.2024.117653_b0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0090-9556(25)06520-1","article-title":"Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members","volume":"23","author":"Stearns","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bmc.2024.117653_b0100","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1021\/tx200337b","article-title":"Reactive aldehyde metabolites from the anti-HIV drug abacavir: amino acid adducts as possible factors in abacavir toxicity","volume":"24","author":"Charneira","year":"2011","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bmc.2024.117653_b0105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0090-9556(25)08584-8","article-title":"The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices","volume":"20","author":"Stearns","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bmc.2024.117653_b0110","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0090-9556(25)08163-2","article-title":"N-glucuronidation reactions. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys, and humans","volume":"21","author":"Huskey","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bmc.2024.117653_b0115","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bcp.2008.07.006","article-title":"The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan","volume":"76","author":"Alonen","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2024.117653_b0120","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1021\/cr000025g","article-title":"Comparative QSAR: angiotensin II antagonists","volume":"101","author":"Kurup","year":"2001","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2024.117653_b0125","first-page":"532","article-title":"Comparison of azosemide and furosemide in ascitic patients without and during administration of spironolactone","volume":"20","author":"Rad\u00f3","year":"1982","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.bmc.2024.117653_b0130","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF02089953","article-title":"Clinical and pharmacological investigations of the new saluretic azosemid","volume":"14","author":"Kruck","year":"1978","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2024.117653_b0135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248413497257","article-title":"Diuretics: a review and update","volume":"19","author":"Roush","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.bmc.2024.117653_b0140","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0090-9556(25)00282-X","article-title":"Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay","volume":"8","author":"Smith","year":"1980","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bmc.2024.117653_b0145","first-page":"812","article-title":"Pharmacokinetics of azosemide in patients with T-drain after cholecystectomy","volume":"42","author":"Schuchmann","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.bmc.2024.117653_b0150","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1021\/jm00085a004","article-title":"Development of a series of phenyltetrazole leukotriene D4 (LTD4) receptor antagonists","volume":"35","author":"Harper","year":"1992","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0155","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1021\/jm00387a018","article-title":"Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives","volume":"30","author":"Marshall","year":"1987","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0160","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0022-3565(25)21132-6","article-title":"LY171883, 1-<2-hydroxy-3-propyl-4-<4-(1H-tetrazol-5-yl) butoxy>phenyl>ethanone, an orally active leukotriene D4 antagonist","volume":"233","author":"Fleisch","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2024.117653_b0165","doi-asserted-by":"crossref","first-page":"eaax2518","DOI":"10.1126\/sciadv.aax2518","article-title":"Structure-based mechanism of cysteinyl leukotriene receptor inhibition by antiasthmatic drugs","volume":"5","author":"Luginina","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.bmc.2024.117653_b0170","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/(SICI)1096-9888(1998110)33:11<1071::AID-JMS719>3.0.CO;2-B","article-title":"Determination of Pranlukast and its metabolites in human plasma by LC\/MS\/MS with PROSPEKTTM on-line solid-phase extraction","volume":"33","author":"Marchese","year":"1998","journal-title":"J Mass Spectrom"},{"key":"10.1016\/j.bmc.2024.117653_b0175","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1248\/bpb.32.688","article-title":"In Vitro Metabolism and Inhibitory Effects of Pranlukast in Human Liver Microsomes","volume":"32","author":"Yoneda","year":"2009","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.bmc.2024.117653_b0180","first-page":"911","article-title":"Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase","volume":"3","author":"Jackman","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2024.117653_b0185","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/oxfordjournals.annonc.a059353","article-title":"Folate-based thymidylate synthase inhibitors as anticancer drugs","volume":"6","author":"Jackman","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2024.117653_b0190","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1016\/0006-2952(83)90150-8","article-title":"Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-((2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-L-glutamic acid (CB3717), on human lymphoblastoid cells","volume":"32","author":"Jackson","year":"1983","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2024.117653_b0195","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0014-2964(81)90206-1","article-title":"A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice","volume":"17","author":"Jones","year":"1981","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmc.2024.117653_b0200","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1021\/jm950912p","article-title":"Structure\u2212Activity Studies of 6-(Tetrazolylalkyl)-Substituted Decahydroisoquinoline-3-carboxylic Acid AMPA Receptor Antagonists. 1. Effects of Stereochemistry, Chain Length, and Chain Substitution","volume":"39","author":"Ornstein","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0205","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1021\/jm950913h","article-title":"Structure\u2212Activity Studies of 6-Substituted Decahydroisoquinoline-3-carboxylic Acid AMPA Receptor Antagonists. 2. Effects of Distal Acid Bioisosteric Substitution, Absolute Stereochemical Preferences, and in Vivo Activity","volume":"39","author":"Ornstein","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0210","first-page":"10124","article-title":"Development of Robust 17(R),18(S)-Epoxyeicosatetraenoic Acid (17,18-EEQ) Analogues as Potential Clinical Antiarrhythmic Agents","volume":"62","author":"Adebesin","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0215","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/cbdd.13043","article-title":"N-acylsulfonamides: Synthetic routes and biological potential in medicinal chemistry","volume":"90","author":"Ammazzalorso","year":"2017","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2024.117653_b0220","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1021\/acs.jmedchem.5b00698","article-title":"Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension","volume":"58","author":"Asaki","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0225","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.107.124248","article-title":"2-[4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug","volume":"322","author":"Keiichi","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2024.117653_b0230","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/00498254.2017.1294277","article-title":"Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys","volume":"48","author":"Ichikawa","year":"2018","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bmc.2024.117653_b0235","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.xphs.2018.09.022","article-title":"Contribution of Human Liver and Intestinal Carboxylesterases to the Hydrolysis of Selexipag <em>In Vitro<\/em>","volume":"108","author":"Imai","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmc.2024.117653_b0240","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/00498254.2018.1444814","article-title":"Cross-species comparison of the metabolism and excretion of selexipag","volume":"49","author":"Ichikawa","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bmc.2024.117653_b0245","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1021\/jm00171a018","article-title":"A novel series of selective leukotriene antagonists: exploration and optimization of the acidic region in 1,6-disubstituted indoles and indazoles","volume":"33","author":"Yee","year":"1990","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0250","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/jm00168a037","article-title":"Evolution of a series of peptidoleukotriene antagonists: synthesis and structure\/activity relationships of 1,3,5-substituted indoles and indazoles","volume":"33","author":"Matassa","year":"1990","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0255","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-200241020-00003","article-title":"Pharmacokinetic Profile of Zafirlukast","volume":"41","author":"Dekhuijzen","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bmc.2024.117653_b0260","first-page":"1069","article-title":"Metabolism and Excretion of Zafirlukast in Dogs","volume":"26","author":"Savidge","year":"1998","journal-title":"Rats, and Mice, Drug Metab Dispos"},{"key":"10.1016\/j.bmc.2024.117653_b0265","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1021\/tx050092b","article-title":"Zafirlukast metabolism by cytochrome P450 3A4 Produces an electrophilic \u03b1, \u03b2-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme","volume":"18","author":"Kassahun","year":"2005","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bmc.2024.117653_b0270","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/jm400164c","article-title":"Discovery of danoprevir (ITMN-191\/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3\/4A protease","volume":"57","author":"Jiang","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0275","unstructured":"https:\/\/www.natap.org\/2006\/DDW\/DDW_30.htm, Accessed 15 October 2023."},{"key":"10.1016\/j.bmc.2024.117653_b0280","unstructured":"https:\/\/www.hyphadiscovery.com\/blog\/metabolism-of-macrocyclic-drugs\/, Accessed 15 October 2023."},{"key":"10.1016\/j.bmc.2024.117653_b0285","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1021\/jm00143a018","article-title":"N-(Methanesulfonyl)-16-phenoxyprostaglandin carboxamides: tissue-selective, uterine stimulants","volume":"24","author":"Schaaf","year":"1981","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0290","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0090-9556(25)08971-8","article-title":"Identification of the major metabolites of the prostaglandin E2-analogue sulprostone in human plasma, and isolation from urine (in vivo) and liver perfusate (in vitro) of female guinea-pigs","volume":"19","author":"Kuhnz","year":"1991","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bmc.2024.117653_b0295","doi-asserted-by":"crossref","unstructured":"S. Sainas, A.C. Pippione, D. Boschi, M.L. Lolli, Chapter Five - Hydroxyazoles as acid isosteres and their drug design applications\u2014Part 1: Monocyclic systems, in: N.A. Meanwell, M.L. Lolli (Eds.) Adv Heterocycl Chem, Academic Press2021, pp. 185-272.","DOI":"10.1016\/bs.aihch.2020.12.001"},{"key":"10.1016\/j.bmc.2024.117653_b0300","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2174\/1568026023393525","article-title":"GABA(A) receptor ligands and their therapeutic potentials","volume":"2","author":"Fr\u00f8lund","year":"2002","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0305","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1021\/jm00017a014","article-title":"Partial GABAA Receptor Agonists. Synthesis and in Vitro Pharmacology of a Series of Nonannulated Analogs of 4,5,6,7-Tetrahydroisoxazolo[4,5-c]pyridin-3-ol","volume":"38","author":"Frolund","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0310","doi-asserted-by":"crossref","unstructured":"P. Krogsgaard-Larsen, H. Hjeds, E. Falch, F.S. J\u00d8Rgensen, L. Nielsen, Recent Advances in GABA Agonists, Antagonists and Uptake Inhibitors: Structure\u2013Activity Relationships and Therapeutic Potential, in: B. Testa (Ed.) Adv Drug Res, Academic Press1988, pp. 381-456.","DOI":"10.1016\/B978-0-12-013317-8.50009-5"},{"key":"10.1016\/j.bmc.2024.117653_b0315","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/268053a0","article-title":"A new class of GABA agonist","volume":"268","author":"Krogsgaard-Larsen","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117653_b0320","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0028-3908(79)90009-1","article-title":"Distribution and metabolism of muscimol in the brain and other tissues of the rat","volume":"18","author":"Baraldi","year":"1979","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmc.2024.117653_b0325","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/284064a0","article-title":"New class of glutamate agonist structurally related to ibotenic acid","volume":"284","author":"Krogsgaard-Larsen","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117653_b0330","doi-asserted-by":"crossref","unstructured":"J. Lauridsen, T. Honor\u00e9, P. Krogsgaard-Larsen, Ibotenic Acid Analogues. Synthesis, Molecular Flexibility, and in Vitro Activity of Agonists and Antagonists at Central Glutamic Acid Receptors, J Med Chem, 28 (1985) 668-672.","DOI":"10.1021\/jm50001a022"},{"key":"10.1016\/j.bmc.2024.117653_b0335","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1021\/ml400526d","article-title":"Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction","volume":"5","author":"Cheng","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117653_b0340","doi-asserted-by":"crossref","first-page":"25641","DOI":"10.1074\/jbc.M116.757310","article-title":"Fatty acid binding to the allosteric subunit of cyclooxygenase-2 relieves a tonic inhibition of the catalytic subunit *","volume":"291","author":"Dong","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0345","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/367243a0","article-title":"The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1","volume":"367","author":"Picot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117653_b0350","doi-asserted-by":"crossref","first-page":"eabf1268","DOI":"10.1126\/sciadv.abf1268","article-title":"Ligand recognition, unconventional activation, and G protein coupling of the prostaglandin E2 receptor EP2 subtype","volume":"7","author":"Qu","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.bmc.2024.117653_b0355","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41589-018-0171-8","article-title":"Crystal structure of the endogenous agonist-bound prostanoid receptor EP3","volume":"15","author":"Morimoto","year":"2019","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2024.117653_b0360","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.str.2020.11.007","article-title":"Cryo-EM Structure of the Prostaglandin E Receptor EP4 Coupled to G Protein","volume":"29","author":"Nojima","year":"2021","journal-title":"Structure"},{"key":"10.1016\/j.bmc.2024.117653_b0365","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41589-018-0131-3","article-title":"Ligand binding to human prostaglandin E receptor EP4 at the lipid-bilayer interface","volume":"15","author":"Toyoda","year":"2019","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2024.117653_b0370","article-title":"Molecular basis for lipid recognition by the prostaglandin D2 receptor CRTH2","volume":"118","author":"Liu","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bmc.2024.117653_b0375","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bmcl.2013.11.046","article-title":"The identification of AF38469: An orally bioavailable inhibitor of the VPS10P family sorting receptor Sortilin","volume":"24","author":"Schr\u00f8der","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117653_b0380","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.bmcl.2006.12.021","article-title":"Discovery of novel, non-acidic 1,5-biaryl pyrrole EP1 receptor antagonists","volume":"17","author":"Hall","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117653_b0385","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1016\/j.bmcl.2008.04.018","article-title":"Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy","volume":"18","author":"Hall","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117653_b0390","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1016\/j.bmcl.2008.05.118","article-title":"Discovery of brain penetrant, soluble, pyrazole amide EP1 receptor antagonists","volume":"18","author":"Hall","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117653_b0395","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1016\/j.bmcl.2011.05.047","article-title":"Discovery of a novel series of nonacidic benzofuran EP1 receptor antagonists","volume":"21","author":"Allan","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117653_b0400","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.bmcl.2017.02.028","article-title":"The identification of novel acid isostere based inhibitors of the VPS10P family sorting receptor Sortilin","volume":"27","author":"Andersen","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117653_b0405","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1038\/s41467-018-06703-2","article-title":"A therapeutic approach to pantothenate kinase associated neurodegeneration","volume":"9","author":"Sharma","year":"2018","journal-title":"Nat Comm"},{"key":"10.1016\/j.bmc.2024.117653_b0410","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1021\/jm4016747","article-title":"Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 2. Leveraging Structure-Based Drug Design to Identify Analogues with Improved Pharmacokinetic Profiles","volume":"57","author":"St","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0415","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1021\/jm5018175","article-title":"Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis","volume":"58","author":"Tamayo","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0420","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1021\/acsmedchemlett.1c00682","article-title":"Discovery of Phospholipase D Inhibitors with Improved Drug-like Properties and Central Nervous System Penetrance","volume":"13","author":"May-Dracka","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117653_b0425","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1021\/acs.jmedchem.8b00076","article-title":"Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors","volume":"61","author":"Grimster","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0430","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1021\/acsmedchemlett.0c00575","article-title":"Discovery of a Series of Pyrazinone ROR\u03b3 Antagonists and Identification of the Clinical Candidate BI 730357","volume":"12","author":"Harcken","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117653_b0435","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1021\/acsmedchemlett.9b00158","article-title":"Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2","volume":"10","author":"von Berg","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117653_b0440","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1021\/acs.jmedchem.5b00773","article-title":"Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors","volume":"58","author":"Bamborough","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0445","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1126\/science.271.5246.163","article-title":"Cation-\u03c0 Interactions in Chemistry and Biology: A New View of Benzene, Phe, Tyr, and Trp","volume":"271","author":"Dougherty","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.bmc.2024.117653_b0450","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1021\/ar300265y","article-title":"The Cation\u2212\u03c0 Interaction","volume":"46","author":"Dougherty","year":"2013","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmc.2024.117653_b0455","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1021\/cr9603744","article-title":"The Cation\u2212\u03c0 Interaction","volume":"97","author":"Ma","year":"1997","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2024.117653_b0460","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/prot.20417","article-title":"Cation\u2013\u03c0 interactions in protein\u2013protein interfaces","volume":"59","author":"Crowley","year":"2005","journal-title":"Proteins"},{"key":"10.1016\/j.bmc.2024.117653_b0465","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1006\/jmbi.1994.1022","article-title":"Planar Stacking Interactions of Arginine and Aromatic Side-Chains in Proteins","volume":"235","author":"Flocco","year":"1994","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmc.2024.117653_b0470","doi-asserted-by":"crossref","first-page":"9459","DOI":"10.1073\/pnas.96.17.9459","article-title":"Cation-\u03c0 interactions in structural biology","volume":"96","author":"Gallivan","year":"1999","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bmc.2024.117653_b0475","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1039\/C7SC04905F","article-title":"Cation\u2013\u03c0 interactions in protein\u2013ligand binding: theory and data-mining reveal different roles for lysine and arginine","volume":"9","author":"Kumar","year":"2018","journal-title":"Chem Sci"},{"key":"10.1016\/j.bmc.2024.117653_b0480","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1021\/acs.jafc.8b00758","article-title":"\u03c0\u2013Cation Interactions in Molecular Recognition: Perspectives on Pharmaceuticals and Pesticides","volume":"66","author":"Liang","year":"2018","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0485","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1021\/ja043475p","article-title":"Structural and Thermodynamic Studies on Cation\u2212\u03a0 Interactions in Lectin\u2212Ligand Complexes: High-Affinity Galectin-3 Inhibitors through Fine-Tuning of an Arginine\u2212Arene Interaction","volume":"127","author":"S\u00f6rme","year":"2005","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2024.117653_b0490","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1002\/chem.200701932","article-title":"Double Affinity Amplification of Galectin-Ligand Interactions through Arginine-Arene Interactions: Synthetic, Thermodynamic, and Computational Studies with Aromatic Diamido Thiodigalactosides","volume":"14","author":"Cumpstey","year":"2008","journal-title":"Chem Eur J"},{"key":"10.1016\/j.bmc.2024.117653_b0495","doi-asserted-by":"crossref","first-page":"11084","DOI":"10.1021\/acs.jmedchem.2c00517","article-title":"Identification of Monosaccharide Derivatives as Potent, Selective, and Orally Bioavailable Inhibitors of Human and Mouse Galectin-3","volume":"65","author":"Liu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0500","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1021\/acs.jmedchem.5b00171","article-title":"Discovery of CREBBP Bromodomain Inhibitors by High-Throughput Docking and Hit Optimization Guided by Molecular Dynamics","volume":"59","author":"Xu","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0505","doi-asserted-by":"crossref","unstructured":"A.M. Taylor, A. C\u00f4t\u00e9, M.C. Hewitt, R. Pastor, Y. Leblanc, C.G. Nasveschuk, F.A. Romero, T.D. Crawford, N. Cantone, H. Jayaram, J. Setser, J. Murray, M.H. Beresini, G. de Leon Boenig, Z. Chen, A.R. Conery, R.T. Cummings, L.A. Dakin, E.M. Flynn, O.W. Huang, S. Kaufman, P.J. Keller, J.R. Kiefer, T. Lai, Y. Li, J. Liao, W. Liu, H. Lu, E. Pardo, V. Tsui, J. Wang, Y. Wang, Z. Xu, F. Yan, D. Yu, L. Zawadzke, X. Zhu, X. Zhu, R.J. Sims, III, A.G. Cochran, S. Bellon, J.E. Audia, S. Magnuson, B.K. Albrecht, Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP\/EP300 Bromodomain Inhibitor (CPI-637), ACS Med Chem Lett, 7 (2016) 531-536.","DOI":"10.1021\/acsmedchemlett.6b00075"},{"key":"10.1016\/j.bmc.2024.117653_b0510","doi-asserted-by":"crossref","first-page":"8889","DOI":"10.1021\/acs.jmedchem.6b00774","article-title":"Development of Selective CBP\/P300 Benzoxazepine Bromodomain Inhibitors","volume":"59","author":"Popp","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0515","doi-asserted-by":"crossref","first-page":"9308","DOI":"10.1021\/ja412434f","article-title":"Discovery and Optimization of Small-Molecule Ligands for the CBP\/p300 Bromodomains","volume":"136","author":"Hay","year":"2014","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2024.117653_b0520","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1021\/acs.jmedchem.6b01839","article-title":"Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain","volume":"60","author":"Denny","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0525","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1002\/anie.201402750","article-title":"A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced-Fit Pocket Stabilized by a Cation\u2013\u03c0 Interaction","volume":"53","author":"Rooney","year":"2014","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2024.117653_b0530","doi-asserted-by":"crossref","first-page":"10926","DOI":"10.1039\/C6OB02234K","article-title":"Cation\u2013\u03c0 interactions in CREBBP bromodomain inhibition: an electrostatic model for small-molecule binding affinity and selectivity","volume":"14","author":"Cortopassi","year":"2016","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0535","first-page":"973","article-title":"A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease, Nature","volume":"11","author":"Dale","year":"2015","journal-title":"Chem Biol"},{"key":"10.1016\/j.bmc.2024.117653_b0540","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1021\/jm501436m","article-title":"Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen","volume":"58","author":"Mallinger","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0545","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1021\/acs.jmedchem.5b01685","article-title":"Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19","volume":"59","author":"Mallinger","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0550","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/acsmedchemlett.5b00278","article-title":"Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8\/19 Knockout Cells","volume":"7","author":"Koehler","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117653_b0555","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-020-2374-x","article-title":"The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K","volume":"585","author":"S\u0142abicki","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117653_b0560","doi-asserted-by":"crossref","unstructured":"Z. Kozicka, D.J. Suchyta, V. Focht, G. Kempf, G. Petzold, M. Jentzsch, C. Zou, C. Di Genua, K.A. Donovan, S. Coomar, M. Cigler, C. Mayor-Ruiz, J.L. Schmid-Burgk, D. H\u00e4ussinger, G.E. Winter, E.S. Fischer, M. S\u0142abicki, D. Gillingham, B.L. Ebert, N.H. Thom\u00e4, Design principles for cyclin K molecular glue degraders, Nature Chem Biol, In Press (2023) doi: 10.1038\/s41589-41023-01409-z.","DOI":"10.1038\/s41589-023-01409-z"},{"key":"10.1016\/j.bmc.2024.117653_b0565","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1038\/s41467-019-11142-8","article-title":"Molecular mechanism of setron-mediated inhibition of full-length 5-HT3A receptor","volume":"10","author":"Basak","year":"2019","journal-title":"Nat Comm"},{"key":"10.1016\/j.bmc.2024.117653_b0570","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/embor.2012.189","article-title":"Structural basis of ligand recognition in 5-HT3 receptors","volume":"14","author":"Kesters","year":"2013","journal-title":"EMBO Rep"},{"key":"10.1016\/j.bmc.2024.117653_b0575","doi-asserted-by":"crossref","first-page":"9600","DOI":"10.1021\/acs.jmedchem.9b01030","article-title":"Structural Basis for Achieving GSK-3\u03b2 Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery","volume":"62","author":"Bernard-Gauthier","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0580","doi-asserted-by":"crossref","first-page":"9601","DOI":"10.1002\/anie.201603797","article-title":"Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging","volume":"55","author":"Liang","year":"2016","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2024.117653_b0585","doi-asserted-by":"crossref","unstructured":"G. Deng, B. Zhao, Y. Ma, Q. Xu, H. Wang, L. Yang, Q. Zhang, T.B. Guo, W. Zhang, Y. Jiao, X. Cai, J. Zhang, H. Liu, X. Guan, H. Lu, J. Xiang, J.D. Elliott, X. Lin, F. Ren, Novel complex crystal structure of prolyl hydroxylase domain-containing protein 2 (PHD2): 2,8-Diazaspiro[4.5]decan-1-ones as potent, orally bioavailable PHD2 inhibitors, Bioorg Med Chem, 21 (2013) 6349-6358.","DOI":"10.1016\/j.bmc.2013.08.046"},{"key":"10.1016\/j.bmc.2024.117653_b0590","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ejmech.2009.12.019","article-title":"Structure of aldehyde reductase in ternary complex with a 5-arylidene-2,4-thiazolidinedione aldose reductase inhibitor","volume":"45","author":"Carbone","year":"2010","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117653_b0595","doi-asserted-by":"crossref","first-page":"14216","DOI":"10.1021\/ja036096p","article-title":"Multiple Intermolecular Interaction Modes of Positively Charged Residues with Adenine in ATP-Binding Proteins","volume":"125","author":"Mao","year":"2003","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2024.117653_b0600","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117653_b0605","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1021\/acsmedchemlett.2c00454","article-title":"Discovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors","volume":"14","author":"Torrente","year":"2023","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117653_b0610","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1021\/acs.jmedchem.2c02132","article-title":"Discovery of Nanomolar DCAF1 Small Molecule Ligands","volume":"66","author":"Li","year":"2023","journal-title":"J Med Chem"}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624000671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624000671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:56:46Z","timestamp":1756745806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624000671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":122,"alternative-id":["S0968089624000671"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117653","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioisoteres for carboxylic acids: From ionized isosteres to novel unionized replacements","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117653"}}